About the study
This Phase 2 proof-of-concept study (ACT18018) evaluated two dosing regimens of itepekimab, an investigational anti-IL-33 antibody, compared with placebo in adults with non-cystic fibrosis bronchiectasis. The main goal was to see whether it reduced the rate of moderate or severe flare-ups over 24 to 52 weeks of treatment.
Who took part
The study enrolled people who:
- Were 18 to 85 years old
- Had non-cystic fibrosis bronchiectasis with at least 2 moderate or 1 severe flare-up in the prior year
Status at Veritas
This study has been completed. It is no longer enrolling, and it is listed here as part of Veritas Clinical Research's track record as a research site.
Learn more
The full study record, including all eligibility criteria and outcome measures, is on ClinicalTrials.gov (NCT06280391).